Get the content you want anytime you want.
ID Week 2018

Select coverage from ID Week 2018 is included below:

Baloxavir Marboxil Significantly Reduces Time to Improvement of Flu Complications
The phase 3 CAPSTONE-2 trial shows treatment with baloxavir marboxil significantly reduced the time to improvement of flu symptoms compared with placebo.
Top 5 Key Takeaways from ID Week 2018
ID Week 2018 was held October 2-7, 2018, in San Francisco, California. The conference featured results of new studies on a variety of infectious disease topics as well as advancements being made in the field. Here are 5 key takeaways from the meeting. 
Nearly Half of Outpatient Antibiotics Prescribed Without Infection Diagnosis
A study of more than 500 outpatient clinics reveals a new view of antibiotic overprescribing practices in the United States.
Top Takeaways from ID Week 2018
We sat down with several infectious disease experts to learn more about their research and asked them to share what they’re taking home from ID Week 2018.
Penicillin: Once Allergic Does Not Mean Always Allergic
Approximately 10% of US patients report having an allergic relation to penicillin, yet only 1% of the population are truly allergic.
Use of Oritavancin to Expedite Discharge Proves Cost-Effective in ABSSSI Patients
Cristen Whittaker, PharmD, explains the findings of an analysis that compared length of stay, readmission, and costs in patients with ABSSSIs who received oritavancin or vancomycin.
Cytomegalovirus Vaccine Candidate Found to Be Safe & Immunogenic in First-in-Humans Trial
An eVLP cytomegalovirus (CMV) vaccine was found to be safe and immunogenic at very low doses in healthy seronegative adults.
Comparison of Ceftolozane/Tazobactam vs Polymyxin/Amingoglycoside for Treatment of MDR/XDR <i>Pseudomonas aeruginosa</i>
Jason Pogue, PharmD, BCPS-AQID, discusses the need for real-world data to support Ceftolozane/tazobactam and shares the findings of his comparative study on using the regimen to treat MDR/XDR Pseudomonas aeruginosa.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?